Sutro Biopharma, Inc.STRONASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-1348.70%
↓ 1359% below average
Average (34q)
-92.43%
Historical baseline
Range
High:198.04%
Low:-1348.70%
Volatility
-1673.5%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -1348.70% |
| Q2 2025 | 95.12% |
| Q1 2025 | -4.99% |
| Q4 2024 | 3.92% |
| Q3 2024 | -39.51% |
| Q2 2024 | 13.97% |
| Q1 2024 | -231.14% |
| Q4 2023 | 198.04% |
| Q3 2023 | 4.69% |
| Q2 2023 | -9.33% |
| Q1 2023 | 14.19% |
| Q4 2022 | -132.07% |
| Q3 2022 | -9.45% |
| Q2 2022 | 50.48% |
| Q1 2022 | -11.69% |
| Q4 2021 | -1.04% |
| Q3 2021 | -253.64% |
| Q2 2021 | 48.42% |
| Q1 2021 | 23.48% |
| Q4 2020 | -133.99% |
| Q3 2020 | 35.33% |
| Q2 2020 | 14.41% |
| Q1 2020 | -29.75% |
| Q4 2019 | -16.07% |
| Q3 2019 | 6.94% |
| Q2 2019 | 4.07% |
| Q1 2019 | -335.60% |
| Q4 2018 | 67.76% |
| Q3 2018 | 15.97% |
| Q2 2018 | -3.29% |
| Q1 2018 | 22.84% |
| Q4 2017 | -1324.23% |
| Q3 2017 | 29.91% |
| Q2 2017 | 0.00% |
| Q1 2017 | 0.00% |